Documents

Flat revenue and ~5% NPAT growth expected in FY 2027, despite Vifor headwinds.

FY 2026 guidance cut, major impairments flagged, but transformation and growth plans on track.

Revenue and profit fell, but guidance and buyback expanded as growth expected to rebound.

High single-digit IG growth, cost savings, and innovation drive robust, sustainable returns.

Growth will accelerate with U.S. market recovery, new vaccine launches, and global expansion.

AGM highlighted robust FY2025 results, cost-saving plans, board changes, and a remuneration strike.

Strong FY2025 growth, major transformation, Seqirus demerger, and robust FY2026 outlook.

Strong H1 FY25 growth and innovation drive a positive long-term outlook for this biotech leader.

CSL projects continued growth in FY25, driven by innovation and global expansion.

Solid H1 growth with strong Behring, Vifor, and reaffirmed double-digit FY2025 earnings outlook.

Strong FY24 results, global expansion, and strategic R&D drive future growth amid Vifor challenges.

Key products near approval as R&D pivots, innovates, and expands patient-focused pipeline.